Analysts Issue Forecasts for PMN FY2026 Earnings

Promis Neurosciences (NASDAQ:PMN – Free Report) – Brookline Capital Markets boosted their FY2026 earnings estimates for shares of Promis Neurosciences in a research note issued to investors on Friday, November 13th. Brookline Capital Markets analyst F. Ahmed now forecasts that the company will post earnings of ($4.93) per share for the year, up from their prior forecast of ($5.21). The consensus estimate for Promis Neurosciences’ current full-year earnings is ($4.82) per share. Brookline Capital Markets also issued estimates for Promis Neurosciences’ Q4 2026 earnings at ($1.47) EPS, Q1 2027 earnings at ($1.88) EPS, Q2 2027 earnings at ($1.46) EPS, Q3 2027 earnings at ($1.58) EPS and FY2027 earnings at ($6.69) EPS.

Promis Neurosciences (NASDAQ:PMN – Get Free Report) last announced its earnings results on Thursday, November 12th. The company reported ($0.89) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.28) by $0.39.

Several other brokerages have also recently weighed in on PMN. HC Wainwright reissued a “buy” rating on shares of Promis Neurosciences in a research note on Monday, October 12th. Wall Street Zen raised Promis Neurosciences from a “sell” rating to a “hold” rating in a research note on Saturday. Roth Capital lowered their price objective on Promis Neurosciences to $15.00 and set a “buy” rating for the company in a research note on Monday, November 2nd. Chardan Capital set a $20.00 target price on Promis Neurosciences and gave the stock a “buy” rating in a report on Monday, July 27th. Finally, Guggenheim reiterated a “buy” rating and issued a $69.00 target price (up from $35.00) on shares of Promis Neurosciences in a report on Tuesday, July 28th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $30.50.

Get Our Latest Stock Analysis on Promis Neurosciences

Promis Neurosciences Stock Down 3.0%

Shares of NASDAQ:PMN opened at $3.21 on Wednesday. Promis Neurosciences has a 12 month low of $2.78 and a 12 month high of $27.40. The company has a 50-day moving average price of $8.80 and a 200 day moving average price of $12.52.

Insider Buying and Selling at Promis Neurosciences

In other news, Director Eugene Williams bought 26,500 shares of Promis Neurosciences stock in a transaction dated Wednesday, November 4th. The shares were acquired at an average price of $3.43 per share, with a total value of $90,895.00. Following the completion of the purchase, the director owned 40,213 shares in the company, valued at $137,930.59. The trade was a 193.25% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Neil Cashman bought 10,000 shares of the stock in a transaction dated Monday, November 2nd. The stock was purchased at an average price of $3.86 per share, with a total value of $38,600.00. Following the acquisition, the insider directly owned 14,532 shares in the company, valued at approximately $56,093.52. The trade was a 220.65% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last three months, insiders bought 37,816 shares of company stock worth $134,746. Insiders own 1.50% of the company’s stock.

Institutional Trading of Promis Neurosciences

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Janus Henderson Group PLC bought a new stake in Promis Neurosciences in the first quarter worth about $16,418,000. Ally Bridge Group NY LLC boosted its position in shares of Promis Neurosciences by 66.1% during the first quarter. Ally Bridge Group NY LLC now owns 414,219 shares of the company’s stock valued at $5,261,000 after buying an additional 164,880 shares during the period. Yu Fan purchased a new position in shares of Promis Neurosciences during the first quarter valued at approximately $4,188,000. ADAR1 Capital Management LLC purchased a new position in shares of Promis Neurosciences during the first quarter valued at approximately $1,211,000. Finally, Seven Fleet Capital Management LP bought a new position in shares of Promis Neurosciences during the first quarter valued at approximately $135,000. 50.13% of the stock is owned by hedge funds and other institutional investors.

Promis Neurosciences Company Profile

(Get Free Report)

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company developing antibody-based treatments for neurodegenerative diseases. Its research focuses on misfolded proteins that may contribute to these conditions. The company’s technology is designed to identify disease-associated forms of proteins while distinguishing them from their normally functioning counterparts. Its lead program, PMN310, is an antibody candidate targeting toxic amyloid-beta oligomers for the potential treatment of Alzheimer’s disease.

Read More

Earnings History and Estimates for Promis Neurosciences (NASDAQ:PMN)

Receive News & Ratings for Promis Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Promis Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.